COMPANY NEWS
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC? Absorbable Dressing in Mainland China
2023.04.11
Download
Hong Kong, 11 April 2023
Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement (“Agency Agreement”) with Gunze Medical Devices (Shenzhen) Ltd. ("Gunze Shenzhen"), a wholly-owned subsidiary of Gunze Limited ("Gunze") in Japan, for PELNAC® Absorbable Dressing ("PELNAC®"), for a product manufactured by Gunze. Pursuant to the Agency Agreement, Essex Medipharma will be the exclusive agent of PELNAC® in Mainland China for a period of 5 years, starting from 2023 to 2027.
PELNAC®, the world's leading artificial dermis product, consists of a collagen sponge layer, which provides a scaffold for cellular invasion and capillary growth, and a silicone film layer, which is reinforced with non-adhesive gauze. It is suitable for full skin defects: (1) Full-thickness burns, (2) Traumatic skin defect wounds, (3) Skin defects after tumor or nevus removal, (4) Sites of skin flap extraction. PELNAC® is not only available in Mainland China and Japan, but has also obtained the CE marking in the EU and FDA approval in the US.
PELNAC® works well with Essex’s bFGF formulated products, the combination of the two products has a synergistic effect that would accelerate the vascularization and improve the viability rate in wounds repair and healing.
The Group believes that with its strong marketing system and extensive distribution network, this cooperation will accelerate the market expansion of PELNAC® in Mainland China and will further strengthen the Group's development in the field of wounds healing for the clinical needs of more patients.
About Gunze Shenzhen
Gunze Medical Devices (Shenzhen) Limited was established in 2010 as a wholly owned subsidiary of Gunze Limited in China, focusing on the development, production and sales of regenerative medicine, and is responsible for the registration, marketing and after-sales management of Gunze Limited's absorbable medical materials in China. Its main products include absorbable dressing, PLLA bioabsorbable bone fixation devices, absorbable reinforcement felt and absorbable artificial dura mater, which are widely used in various departments such as thoracic surgery, orthopedics, burn surgery and neurosurgery.
About Essex
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and 適麗順®(Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,900 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement (“Agency Agreement”) with Gunze Medical Devices (Shenzhen) Ltd. ("Gunze Shenzhen"), a wholly-owned subsidiary of Gunze Limited ("Gunze") in Japan, for PELNAC® Absorbable Dressing ("PELNAC®"), for a product manufactured by Gunze. Pursuant to the Agency Agreement, Essex Medipharma will be the exclusive agent of PELNAC® in Mainland China for a period of 5 years, starting from 2023 to 2027.
PELNAC®, the world's leading artificial dermis product, consists of a collagen sponge layer, which provides a scaffold for cellular invasion and capillary growth, and a silicone film layer, which is reinforced with non-adhesive gauze. It is suitable for full skin defects: (1) Full-thickness burns, (2) Traumatic skin defect wounds, (3) Skin defects after tumor or nevus removal, (4) Sites of skin flap extraction. PELNAC® is not only available in Mainland China and Japan, but has also obtained the CE marking in the EU and FDA approval in the US.
PELNAC® works well with Essex’s bFGF formulated products, the combination of the two products has a synergistic effect that would accelerate the vascularization and improve the viability rate in wounds repair and healing.
The Group believes that with its strong marketing system and extensive distribution network, this cooperation will accelerate the market expansion of PELNAC® in Mainland China and will further strengthen the Group's development in the field of wounds healing for the clinical needs of more patients.
~ End ~
About Gunze Shenzhen
Gunze Medical Devices (Shenzhen) Limited was established in 2010 as a wholly owned subsidiary of Gunze Limited in China, focusing on the development, production and sales of regenerative medicine, and is responsible for the registration, marketing and after-sales management of Gunze Limited's absorbable medical materials in China. Its main products include absorbable dressing, PLLA bioabsorbable bone fixation devices, absorbable reinforcement felt and absorbable artificial dura mater, which are widely used in various departments such as thoracic surgery, orthopedics, burn surgery and neurosurgery.
About Essex
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and 適麗順®(Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,900 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Related news
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024-03-18
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-08-16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-07-26
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-03-08
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-10-27
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-20
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2021-01-29
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-08-02
粵公網安備 44049102496184號